"Dr. Manshadi's approach which has helped him to succeed in his field of cardiology is his desire for teamwork and having a balance in life and in practice. Professionally he balances his work in private practice, in academics, and in the leadership activities for his Cardiac society which in return helps him to give to his patients a sound and balanced approach in treatment which translates into better health for his patients. While his credentials and capabilities are impressive, so too is Dr. Manshadi’s approach to patient care. He will treat you with the utmost concern and compassion and provide you with the emotional support you need. Your appointments with him are unhurried and informative, and he will explain everything in simple."

During the past decade, Manshadi Heart Institute, Inc conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manshadi Heart Institute, Inc" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator, "Manshadi Heart Institute, Inc." with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Manshadi Heart Institute, Inc" are "Heart Failure" (2 trials), "Acute Coronary Syndromes" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Diabetes" (1 trials). Many other conditions were trialed in "Manshadi Heart Institute, Inc" in a lesser frequency.

Most popular intervention types in "Manshadi Heart Institute, Inc" are "Drug" (4 trials), "Device" (1 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Empagliflozin" (2 trials), "Acetylsalicylic acid" (1 trials), "Acetylsalicylic acid placebo" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Manshadi Heart Institute, Inc" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Manshadi Heart Institute, Inc". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Manshadi Heart Institute, Inc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Manshadi Heart Institute, Inc, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".